Treatment of Acute Hepatitis C

Yıl 2016, Cilt: 6 Sayı: 1, 40 - 44, 01.03.2016

İlkay Bozkurt

https://doi.org/10.5799/jmid.328768

Öz

An acute hepatitis C virus (HCV) infection is an uncommonly encountered illness. Patients infected with the HCV commonly
tend to be asymptomatic because of spontaneous viral clearance or chronic infection. Early antiviral treatment
may be beneficial especially in symptomatic cases. Antiviral therapy with an (IFN)-based regimen is standard except in
the instance of a human immunodeficiency virus (HIV) coinfection. The efficacy of HCV therapy has been restricted by
the side effects of treatment. Advances in the treatment options of chronic HCV infection have resulted in the development
of many new antiviral drugs that may allow for simplified and shortened treatments with increased tolerability and
efficacy in patients with acute HCV infection. J Microbiol Infect Dis 2016;6(1): 40-44

Anahtar Kelimeler

Acute hepatitis C, treatment, genotype, interferon, ribavirin

Kaynakça

• 1. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103:1283-1297.
• 2. Boesecke C, Rockstroh JK. Acute hepatitis C in patients with HIV. Semin Liver Dis 2012;32:130-137.
• 3. Cox AL, Netski DM, Mosbruger T, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Di. 2005;40:951-958.
• 4. European Association for the Study of the Liver (EASL) Available from: URL: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/management-of-hepatitis-c-virusinfection-revised-version/report/4.
• 5. Irving WL, Salmon D, Boucher C, et al. Acute hepatitis C virus infection. Euro Surveill 2008;13:18879.
• 6. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Di 2005;9:383-398.
• 7. Chung RT. Acute hepatitis C virus infection. Clin Infect Dis 2005;41:14-17.
• 8. Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother 2010;65:4-9.
• 9. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepa. 2006;13:34-41.
• 10. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C:high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
• 11. Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003;37:60-64.
• 12. Corey KE, Mendez-Navarro J, Gorospe EC, et al. Early treatmentimproves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010;17:201-217.
• 13. Licata A, Di Bona D, Schepis F, et al. When and how to treat acute hepatitis C? J Hepatol 2003;39:1056-1062.
• 14. Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632-638.
• 15. Deterding K, Grüner N, Buggisch P, et al. Hep-Net Acute HCV-III Study Group. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013;13:497-506.
• 16. Broers B, Helbling B, François A, et al. Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323-328.
• 17. Wiegand J, Deterding K, Cornberg M, et al. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 2008;62:860-865.
• 18. Deutsch M, Papadopoulos N, Hadziyannis ES, et al. Clinical characteristics, spontaneous clearance and treatment outcome of acute hepatitis C: a single tertiary center experience. Saudi J Gastroenterol 2013;19:81-85.
• 19. De Rosa FG, Bargiacchi O, Audagnotto S, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother 2006;57:360-363.
• 20. Ghany MG, Strader DB, Thomas DL, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335- 1374.
• 21. Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
• 22. Jaeckel E, Cornberg M, Wedemeyer H, et al. German Acute Hepatitis C Therapy Group.Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457.
• 23. Lampertico P, Rumi M, Romeo R, et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994;19:19-22.
• 24. Poynard T, Regimbeau C, Myers RP, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev. 2002;CD000369.
• 25. Serpaggi J, Chaix ML, Batisse D, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV- 1-infected men and inefficacy of early antiviral therapy AIDS. 2006;20:233-240.
• 26. Corey KE, Ross AS, Wurcel A, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 2006;4:1278-1282.
• 27. Nunnari G, Montineri A, Portelli V, et al. The useof peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Eur Rev Med Pharmacol Sci 2012;16:1013- 1016.
• 28. Santantonio T, Fasano M, Sagnelli E, et al. Acute Hepatitis C Study Group. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin. Hepatology. 2014;59:2101-2109.
• 29. Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006;20:1157-1161.
• 30. Fierer DS, Dieterich DT, Mullen MP, et al. New York Acute Hepatitis C SurveillanceNetwork. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014;58:873-879.
• 31. Pawlotsky JM. Hepatitis C treatment: the data flood goes onan update from the liver meeting 2014. Gastroenterology 2015;148:468-479.
• 32. Hullegie SJ, Arends JE, Rijnders BJ, et al. Current knowledge and future perspectives on acute hepatitis C infection. Clin Microbiol Infect 2015;21:797.
• 33. Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol 2012;57:1349-1360.
• 34. Grebely J, Page K, Sacks-Davis R, et al. In C3 Study Group. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014;59:109-120.
• 35. Mosley JW, Operskalski EA, Tobler LH, et al. Transfusiontransmitted Viruses Study and Retrovirus Epidemiology Donor Study Groups. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008;15:120-128.
• 36. Tomkins SE, Rice BD, Roy K, et al. Universal treatment success among healthcare workers diagnosed with occupationally acquired acute hepatitis C. J Hosp Infect 2015;89:69-71.
• 37. Loomba R, Rivera MM, McBurney R, et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011;33:559-565.
• 38. Sharaf Eldin N, Ismail S, Mansour H, et al. Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. PLoS One. 2008;3:e4085.
• 39. Ishikane M, Watanabe K, Tsukada K, et al. Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study. PLoS One 2014;9:e100517.
• 40. Liu CH, Liang CC, Liu CJ, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 2010;51:541-549.